Mhc class ii haplotype specific immunodominancy of peptides derived from rsv fusion (f) and attachement (g) proteins
CA 2489907 A1 · Owner: Van Els, Cecile Antoinette Carola Maria · Inventors: Van Bleek, Gerarda Maria; Boog, Marie-Claire Josefa Pia; Van Els, Cecile Antoinette Carola Maria
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates immunodominant peptides derived from human respiratory syncytial virus (H-RSV) that may be used in ex vivo diagnosis of immune responses to H-RSV. The immunodominant peptides are derived from the H- RSV Fusion (F) and Attachment (G) proteins and are capable of inducing an antigen specific CD4+ T cell response ex vivo in a MHC class 11 haplotype restricted manner. The immunodominant H-RSV-derived peptides may further be used in methods for vaccination against H-RSV preferably in a MHC class 11 , haplotype specific manner.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 20, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended June 20, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 20, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.